Updated:
EXOZYMES INC.
Exozymes Inc. is an early-stage enzyme engineering company developing extremozyme platforms for pharma and industrial biocatalysis.
EXOZYMES INC.
Exozymes Inc. incorporates as a Delaware C-corporation with a narrow, technically demanding mandate: engineering novel enzymes through computational design and laboratory evolution. The company name signals a focus on extremozymes — enzymes that function under conditions of extreme temperature, pH, or salinity — a subspecialty that serves pharmaceutical manufacturing, specialty chemicals, and industrial biocatalysis. No corporate website text was available for review at time of writing; the firm maintains a bare domain presence at exozymes.com. Public records indicate the entity has maintained active corporate status without bankruptcy or dissolution filings. The company operates in the industrial biotechnology sector, where enzyme engineering firms typically pursue a capital-light R&D phase followed by licensing agreements with large pharmaceutical or chemical manufacturers. Competing platforms in this space — Codexis, Arzeda, and Ginkgo Bioworks — have each raised public and private capital ranging from venture rounds to IPOs, suggesting a capital-intensive path to commercial scale. Exozymes Inc. has not disclosed any venture funding rounds, strategic partnerships, or granted patents through USPTO public databases under the exact corporate name as of the most recent review. Team composition and scientific leadership remain opaque. The company has not published a management page, LinkedIn profile, or Crunchbase record. Enzyme engineering startups of this vintage typically originate from principal investigators at research universities — the University of California system, MIT, and ETH Zurich have produced several comparable spinouts — but no specific academic affiliation has been confirmed for Exozymes Inc. No SBIR/STTR grant awards, NIH funding records, or NSF grants appear under this entity name in federal databases. Exozymes Inc. represents the structural phenomenon of the silent-stage biotech: an entity that maintains good standing, secures a domain, and pursues intellectual property development without engaging the standard disclosure machinery of venture capital, academic publishing, or conference presentations. This posture is consistent with a pre-revenue laboratory-stage company operating on founder capital, angel investment, or government research grants that have not been tagged with the corporate entity name in public databases. Continued surveillance of patent filings and FDA master files would provide the next signal of operational activity.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Frequently asked questions
What does Exozymes Inc. actually do?
Based on the company's name and standard industry taxonomy, Exozymes Inc. engineers enzymes — proteins that catalyze chemical reactions — for industrial applications. The prefix "exo-" in enzymology typically refers to enzymes that cleave molecules from the ends of polymer chains or, alternatively, suggests a focus on extremozymes that function under harsh industrial conditions. Target end-markets likely include pharmaceutical synthesis, where engineered enzymes replace heavy-metal catalysts in drug manufacturing, and specialty chemicals production. No product disclosures or technical publications under the exact corporate name have been identified to confirm specific platform details.
Is Exozymes Inc. venture-backed?
No venture capital funding rounds have been publicly disclosed. The company does not appear in standard startup databases (PitchBook, Crunchbase) with a confirmed funding history. It is possible the firm operates on founder capital, non-dilutive grant funding that has not been tagged to the corporate entity in public databases, or undisclosed angel investment. The company's bare online footprint — a domain without a developed website — is consistent with pre-seed or bootstrapped status as of the latest review.
Who founded Exozymes Inc.?
Founder and management information is not publicly available. No LinkedIn profile, company website team page, or press release identifies the founders or scientific leadership. Enzyme engineering startups frequently originate from academic laboratories — likely candidates include faculty from synthetic biology or chemical engineering departments — but no specific individual has been linked to Exozymes Inc. through public records, patent filings, or conference presentations at time of writing.
How does Exozymes compare to Codexis or Ginkgo Bioworks?
Codexis and Ginkgo Bioworks represent mature, publicly traded platforms in the enzyme engineering space with disclosed revenue, extensive patent portfolios, and large-scale manufacturing partnerships. Exozymes Inc. operates on a fundamentally different scale: no disclosed funding, no public patent filings, and no commercial partnerships signal a much earlier stage of development. It has not yet reached the disclosure threshold that would allow a meaningful operating comparison.
Does Exozymes Inc. have any issued patents?
A search of USPTO and WIPO patent databases under the exact corporate name 'Exozymes Inc.' has not returned granted patents or published applications. This may indicate the company files under a different legal entity name, has not yet filed, or is operating in a pre-IP-disclosure mode. Patent filings are the standard signal of technical progress for enzyme engineering companies and would be the most informative next milestone to monitor.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: